ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2018
Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 53 citations in OpenAlex.
- Review
- Analysis of Adverse Reactions Associated with the Use ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Real world effectiveness of Hawthorn special extract WS 1442 in a retrospective cohort study from Germany.Scientific reports · 2024Article
- Crataegus pentagyna willd. Fruits, leaves and roots: phytochemicals, antioxidant and antimicrobial potentials.BMC complementary medicine and therapies · 2024Article
- Tejocote Root's Role in Symptomatic Mobitz Type 1 Heart Block: A Compelling Case Report.Cureus · 2023Article
- Perivascular Adipose Tissue Oxidative Stress in Obesity.Antioxidants (Basel, Switzerland) · 2023Review
- Food Applications and Potential Health Benefits of Hawthorn.Foods (Basel, Switzerland) · 2022Review
- Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases.Nutrients · 2022Review
- Ethanol Extract of Chinese Hawthorn (Crataegus pinnatifida) Fruit Reduces Inflammation and Oxidative Stress in Rats with Doxorubicin-Induced Chronic Heart Failure.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Water-Based Extraction of Bioactive Principles from Blackcurrant Leaves andFoods (Basel, Switzerland) · 2020Article
- Roles and Mechanisms of Hawthorn and Its Extracts on Atherosclerosis: A Review.Frontiers in pharmacology · 2020Review
- Optimizing Water-Based Extraction of Bioactive Principles of Hawthorn: From Experimental Laboratory Research to Homemade Preparations.Molecules (Basel, Switzerland) · 2019Article
- Crataegus mexicana (Tejocote) Exposure Associated with Cardiotoxicity and a Falsely Elevated Digoxin Level.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2019Article
- Advantageous Extraction, Cleanup, and UHPLC-MS/MS Detection of Patulin Mycotoxin in Dietary Supplements and Herbal Blends Containing Hawberry fromJournal of analytical methods in chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preparations from Crataegus (hawthorn) have a long history in the treatment of heart failure. WS 1442 is a dry extract from hawthorn leaves with flowers (4-6.6:1), extraction solvent of ethanol 45% (w/w), adjusted to 17.3-20.1% of oligomeric procyanidins. Nonclinical studies show that WS 1442 has positive inotropic and antiarrhythmic properties and protects the myocardium from ischemic damage, reperfusion injury, and hypertension-related hypertrophy, improves endothelial functions such as NO synthesis, and delays endothelial senescence. Randomized, controlled trials in patients with heart failure have demonstrated that the herbal medicinal product increases functional capacity, alleviates disabling symptoms, and improves health-related quality of life, all of which have become important targets of heart failure therapy according to current disease management guidelines. Clinical trials (including a 2-year mortality study with polypharmacy and > 1300 patients exposed) and post-marketing surveillance studies have shown that WS 1442 has a very favorable safety profile both as monotherapy and as add-on therapy, where no drug interactions have been observed. No specific adverse reactions to WS 1442 are known to date. WS 1442 may thus help to close the therapeutic gap between systolic and diastolic heart failure for which evidence of efficacy for other cardioactive drugs is sparse. Scientific evidence shows that WS 1442 is safe and has a beneficial effect in patients with heart failure corresponding to New York Heart Association classes II or III. The benefit-risk assessment for WS 1442 is therefore positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.